Fluorescence Guided Targeted Pelvic Lymph Node Dissection for Intermediate and High Risk Prostate Cancer
- PMID: 25896557
- DOI: 10.1016/j.juro.2015.03.127
Fluorescence Guided Targeted Pelvic Lymph Node Dissection for Intermediate and High Risk Prostate Cancer
Abstract
Purpose: We investigated whether visualization of the drainage system of the prostate by free indocyanine green would lead to identification of all or even more lymph node metastases detected by super-extended pelvic lymph node dissection in an intermediate and high risk patient population with prostate cancer.
Materials and methods: A total of 38 consecutive men with intermediate or high risk prostate cancer according to the D'Amico criteria underwent fluorescence targeted pelvic lymph node dissection during laparoscopic radical prostatectomy. Super-extended pelvic lymph node dissection was added as the control. Patients with neoadjuvant hormonal therapy, macroscopic lymph node involvement or prior transurethral prostate resection were excluded from study. Statistical descriptive methods, and the chi-square test and independent t-test were used to analyze data.
Results: Mean patient age was 64.9 years (range 46 to 74) and mean preoperative prostate specific antigen was 13.8 ng/ml (range 0.3 to 44). A total of 23 (60.5%) and 15 cases (39.5%) were classified as intermediate and high risk, respectively. Fluorescence stained nodes were found on each side in all except 1 patient. A total of 700 lymph nodes (mean ± SD 18.4 ± 8.2 per patient) were removed, of which 531 (75% of all nodes) were fluorescence stained (mean 14 ± 8.07 per patient). Lymph node metastases were found in 15 patients (39.5%). Two patients (5.3%) had a solitary micrometastasis and 3 (7.9%) had nodes containing isolated tumor cells. Metastases were found outside the extended pelvic lymph node dissection template in 5 of 15 patients (33.3%). Three of those 5 patients attained a prostate specific antigen nadir of less than 0.1 ng/ml 6 weeks postoperatively. Fluorescence targeted pelvic lymph node dissection showed superior sensitivity and negative predictive value compared to extended and super-extended pelvic lymph node dissection to detect lymph node metastasis.
Conclusions: Fluorescence targeted pelvic lymph node dissection allows for the lymphatic drainage of the prostate to be identified with great reliability. Since only the nodes draining the prostate are removed, the absolute number of removed nodes is decreased while diagnostic accuracy is increased.
Keywords: diagnosis; fluorescence; lymph node excision; neoplasm metastasis; prostatic neoplasms.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Visualisation of the lymph node pathway in real time by laparoscopic radioisotope- and fluorescence-guided sentinel lymph node dissection in prostate cancer staging.Urology. 2012 Nov;80(5):1080-6. doi: 10.1016/j.urology.2012.05.050. Epub 2012 Sep 15. Urology. 2012. PMID: 22990053
-
Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer.BJU Int. 2013 Jul;112(1):81-8. doi: 10.1111/j.1464-410X.2012.11788.x. Epub 2013 Jan 25. BJU Int. 2013. PMID: 23351148
-
Indocyanine Green Guided Pelvic Lymph Node Dissection: An Efficient Technique to Classify the Lymph Node Status of Patients with Prostate Cancer Who Underwent Radical Prostatectomy.J Urol. 2016 Nov;196(5):1429-1435. doi: 10.1016/j.juro.2016.05.087. Epub 2016 May 25. J Urol. 2016. PMID: 27235788
-
Pelvic node dissection in prostate cancer: extended, limited, or not at all?Curr Opin Urol. 2010 May;20(3):211-7. doi: 10.1097/MOU.0b013e328338405d. Curr Opin Urol. 2010. PMID: 20224412 Review.
-
Advances in sentinel node dissection in prostate cancer from a technical perspective.Int J Urol. 2015 Oct;22(10):898-909. doi: 10.1111/iju.12863. Epub 2015 Jul 14. Int J Urol. 2015. PMID: 26173593 Review.
Cited by
-
A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients.Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2861-2871. doi: 10.1007/s00259-023-06191-7. Epub 2023 Apr 10. Eur J Nucl Med Mol Imaging. 2023. PMID: 37036490 Clinical Trial.
-
Fluorescence-supported lymphography and extended pelvic lymph node dissection in robot-assisted radical prostatectomy: a prospective, randomized trial.World J Urol. 2018 Nov;36(11):1817-1823. doi: 10.1007/s00345-018-2330-7. Epub 2018 May 16. World J Urol. 2018. PMID: 29767326 Clinical Trial.
-
Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph-node invasion.Clin Transl Med. 2025 Apr;15(4):e70288. doi: 10.1002/ctm2.70288. Clin Transl Med. 2025. PMID: 40219635 Free PMC article.
-
Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models.Clin Cancer Res. 2019 Jan 1;25(1):188-200. doi: 10.1158/1078-0432.CCR-18-1382. Epub 2018 Oct 9. Clin Cancer Res. 2019. PMID: 30301826 Free PMC article.
-
Diagnostic Accuracy of Indocyanine Green-stained Sentinel Lymph Nodes in Prostate Cancer Patients: A Systematic Review and Meta-analysis.Eur Urol Open Sci. 2025 Feb 21;74:34-43. doi: 10.1016/j.euros.2025.02.002. eCollection 2025 Apr. Eur Urol Open Sci. 2025. PMID: 40066190 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical